10-Q quarterly report · filed Nov 9, 2026

PUMA BIOTECHNOLOGY, INC. (PBYI) Q3 2026 10-Q Quarterly Report

Short answer

PUMA BIOTECHNOLOGY, INC. (PBYI) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (up 1.1% year over year) with net income of $6M.

Q3 2026 key financials · XBRL

Revenue
$55M
+1.1% YoY · −2.6% QoQ
Net income
$6M
−32.7% YoY · −27.3% QoQ
Operating margin
9.6%
EPS (diluted)
$0.12
−29.4% YoY · −20.0% QoQ

Source: XBRL data from the PUMA BIOTECHNOLOGY, INC. (PBYI) Q3 2026 10-Q on SEC EDGAR. USD.

PUMA BIOTECHNOLOGY, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $55.1M, up from $54.5M YoY, driven by product revenue of $54.1M vs $51.9M
  • Product revenue best performer, up $2.2M; royalty revenue weakest, $0.9M vs $2.6M
  • Gross margin 72.4% vs 77.6% YoY; net margin 10.8% vs 16.2%
  • Operating cash flow $31.6M for nine months vs $27.4M; cash $41.5M plus securities $67.0M
  • Alisertib spending rising; debt fully repaid, while tariffs and China royalty-rate reduction remain headwinds

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Unknown or currently immaterial risks could still materially affect results
  • Forward-looking statements remain subject to actual results differing materially from expectations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PUMA BIOTECHNOLOGY, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.